

Peptide agent against multi-resistant bacteria

Researchers from the University of Regensburg have developed a peptide with strong antimicrobial activity against carbapenem-resistant gram-negative bacteria, which are responsible for a large number of deaths annually. The antimicrobial peptide kills bacteria within hours, also destroying non-replicating bacteria. The peptide strongly reduces inflammation and is therefore especially suitable to improve outcome in septic patients.




Strong anti-inflammatory effect, potentially beneficial in sepsis

Death by antibiotic resistant bacteria is not only caused by direct tissue destruction but also by systemic shedding of the endotoxin lipopolysaccharide (LPS) from the surface of the Gram-negative bacteria causing severe hyperinflammation, ultimately leading to sepsis, organ failure and death.


- 01 especially promising for patients with autoantibodies against endogenous BPI (e.g. in cystic fibrosis, rheumatoid arthritis and SLE)
- 02 antibacterial agent for Gram-negative infections, including infections with multiple drug-resistant bacteria
- 03 fast action (hours), also bactericidal against non-replicating bacteria
- 04 common resistance mechanisms do not affect the scoBPI-based antimicrobial agent

REFERENCES:

-  Holzinger et al, eLife 12:e86369 (2023)



scoBPI quickly eliminates MDR bacteria. Bacterial viability assay performed with a representative *P. aeruginosa* MDR strain. Viable bacteria are seen in green and dead bacteria in red.



Transmission electron microscopy of the representative *P. aeruginosa* MDR isolate shown above, showing disintegrating bacterial cells.

IP RIGHTS

PCT application
filed. EP and US
pending

2022

CHALLENGE

Antimicrobial resistance (AMR) is globally rising over the last decades, partly due to over- or misuse of antibiotics. In 2019, over 3 million deaths were associated with AMR globally. Thereby, the Gram-negative bacteria *Escherichia coli*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* were within the top six pathogens causing death. Around 8% of patients infected with the aforementioned, resistant pathogens will not survive.

INNOVATION

The new peptide-based antimicrobial agent based on an optimized form of the scorpion fish protein BPI (scoBPI) shows very high anti-inflammatory potency towards the endotoxin activity of lipopolysaccharides and a bactericidal activity at nanomolar concentrations against carbapenem-resistant *P. aeruginosa*, *E. coli* and *A. baumannii*. Since the activity of the optimized scoBPI is mediated via membrane perturbation, common resistance mechanisms mediated by e.g. porin loss, efflux pumps and antibiotic-binding or -deactivating proteins do not affect the activity of the antimicrobial peptide.

01 Basic principles observed · 02 Technology concept formulated · 03 Experimental proof of concept · 04 Technology validated in lab · 05 Technology validated in relevant environment · 06 Technology demonstrated in relevant environment · 07 System prototype demonstrated in operational environment · 08 System complete and qualified

TRL 08
TRL 07
TRL 06
TRL 05
TRL 04
TRL 03
TRL 02
TRL 01

Technology Readiness Level (TRL)



BayPAT

Innovation from Research & Science –
BayPAT markets inventions on behalf
of the Bavarian universities and
universities of applied sciences.

An invention of University of
Regensburg

Universität Regensburg

As one of the largest technology transfer offices in Germany, BayPAT evaluates and commercializes innovations from 28 research institutions. With our extensive experience and expertise in patenting and licensing technologies and our comprehensive range of services, we are your partner of choice. For more information visit www.baypat.de

Bayerische Patentallianz GmbH
Dr. Linda Keil
lkeil@baypat.de
+49 (0)89 5480177-30
Prinzregentenstr. 52
80538 München

